The predoctoral Training Program in Biomolecular Pharmacology at Boston University, launched in 1991 to meld quantitative principles of biomedical engineering (BME) with pharmacology and experimental therapeutics, was honored in 1997 with an NIGMS T32 award. In the succeeding 19 years, this university-wide program has provided a supportive learning environment for predoctoral students. The Program includes an innovative curriculum, interdisciplinary laboratory rotations, industrial summer internships, and diverse research training opportunities that span the Medical and Charles-River campuses. Students enter via the Departments of Pharmacology or BME and more recently from the university-wide Graduate Program for Neuroscience (GPN) implemented in 2010. Program trainees in BME and GPN experience an integrated curriculum, designed to provide enriched training in pharmacology coordinated with specialized training in their primary discipline. Trainees in Pharmacology gain access to diverse research and educational experiences that build upon those provided by pharmacology faculty. The core curriculum stresses fundamental pharmacological principles including interactions of bioactive molecules, drug delivery for novel therapeutics, animal models and relevance to the clinic, and challenges for modern drug discovery. The Program, recently enhanced with an NIGMS supplement on reproducibility in research, is structured to train students in the skills of rigorous scientific research, including study design, grant application, and publication. Participating faculty, originally 21 and now 59, contribute expertise in focus areas, including neuropharmacology, vascular and cancer pharmacology, genomics and proteomics, animal models (transgenic and behavioral), structural biology, nanotechnology, systems biology and medicinal chemistry. Career guidance with oversight by faculty and student mentors, strengthened by the BU BEST Award, provides opportunities relevant to their professional goals, whether in academia, government or the private sector. Training duration averages 5.2 years, and graduates compete well for positions in various sectors. There are currently 47 students (39 TGE) in the Program, including 6 TGE from underrepresented minorities. This renewal application seeks funding for 7 trainees each year, an increase reflecting the greater demand of highly qualified candidates for pharmacology training and the expanded research opportunities of faculty participants.

Public Health Relevance

The Program in Biomolecular Pharmacology at Boston University is designed to train predoctoral students in pharmacological research and discovery, combining the fundamental principles of pharmacology with novel approaches drawn from bioinformatics, biophysics, biochemistry, biomedical engineering, chemistry, genetics, molecular medicine and neuroscience. Trainees undertake an integrated curriculum that emphasizes translation of rigorous basic science research and acquisition of scientific skills for careers in academia, government or the private sector.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
2T32GM008541-21
Application #
9358093
Study Section
Training and Workforce Development Subcommittee - D (TWD)
Program Officer
Koduri, Sailaja
Project Start
1997-07-01
Project End
2023-06-30
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
21
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Boston University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Kirkpatrick, Stacey L; Goldberg, Lisa R; Yazdani, Neema et al. (2017) Cytoplasmic FMR1-Interacting Protein 2 Is a Major Genetic Factor Underlying Binge Eating. Biol Psychiatry 81:757-769
Estrada, Larissa I; Robinson, Amy A; Amaral, Ana C et al. (2017) Evaluation of Long-Term Cryostorage of Brain Tissue Sections for Quantitative Histochemistry. J Histochem Cytochem 65:153-171
Varnum, Megan M; Clayton, Kevin A; Yoshii-Kitahara, Asuka et al. (2017) A split-luciferase complementation, real-time reporting assay enables monitoring of the disease-associated transmembrane protein TREM2 in live cells. J Biol Chem 292:10651-10663
Grant, Trevor J; Mehta, Anita K; Gupta, Anamika et al. (2017) STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines. Oncotarget 8:78556-78572
Clayton, Kevin A; Van Enoo, Alicia A; Ikezu, Tsuneya (2017) Alzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy. Front Neurosci 11:680
Weinstein, Zohar B; Zaman, Muhammad H (2017) Quantitative bioassay to identify antimicrobial drugs through drug interaction fingerprint analysis. Sci Rep 7:42644
Mehta, Anita K; Hua, Kevin; Whipple, William et al. (2017) Regulation of autophagy, NF-?B signaling, and cell viability by miR-124 in KRAS mutant mesenchymal-like NSCLC cells. Sci Signal 10:
Lakin, Benjamin A; Patel, Harsh; Holland, Conor et al. (2016) Contrast-enhanced CT using a cationic contrast agent enables non-destructive assessment of the biochemical and biomechanical properties of mouse tibial plateau cartilage. J Orthop Res 34:1130-8
Frame, Alissa A; Carmichael, Casey Y; Wainford, Richard D (2016) Renal Afferents. Curr Hypertens Rep 18:69
Walsh, Kathryn R; Kuwabara, Jill T; Shim, Joon W et al. (2016) Norepinephrine-evoked salt-sensitive hypertension requires impaired renal sodium chloride cotransporter activity in Sprague-Dawley rats. Am J Physiol Regul Integr Comp Physiol 310:R115-24

Showing the most recent 10 out of 109 publications